Matching articles for "Sublinox"
Issue 1667 · January 9, 2023
Expanded Table: Some Oral Drugs for Chronic Insomnia (online only)

View the Expanded Table: Some Oral Drugs for Chronic Insomnia

Med Lett Drugs Ther. 2023 Jan 9; 65(1667):e6-10 doi:10.58347/tml.2023.1667b
View the Expanded Table: Some Oral Drugs for Chronic Insomnia
Issue 1667 · January 9, 2023
Drugs for Chronic Insomnia

Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation training,…

Med Lett Drugs Ther. 2023 Jan 9; 65(1667):1-6 doi:10.58347/tml.2023.1667a
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation training, and cognitive therapy. When CBT-I alone is not effective, pharmacologic treatment should be added.
Issue 1654 · July 11, 2022
Daridorexant (Quviviq) for Insomnia

The FDA has approved daridorexant ( Quviviq – Idorsia), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. Daridorexant is the third orexin receptor…

Med Lett Drugs Ther. 2022 Jul 11; 64(1654):107-10
The FDA has approved daridorexant ( Quviviq – Idorsia), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. Daridorexant is the third orexin receptor antagonist to be approved for this indication; suvorexant (Belsomra) and lemborexant (Dayvigo) were approved earlier.
Issue 1601 · June 29, 2020
Lemborexant (Dayvigo) for Insomnia

The FDA has approved lemborexant ( Dayvigo – Eisai), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. It is the second orexin receptor antagonist to be…

Med Lett Drugs Ther. 2020 Jun 29; 62(1601):97-100
The FDA has approved lemborexant ( Dayvigo – Eisai), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. It is the second orexin receptor antagonist to be approved for this indication; suvorexant ( Belsomra ) was the first.
Issue 1582 · October 7, 2019
Advice for Travelers

Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.

Med Lett Drugs Ther. 2019 Oct 7; 61(1582):153-60
Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.
Issue 1582 · October 7, 2019
Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness (online only)

View the Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness

Med Lett Drugs Ther. 2019 Oct 7; 61(1582):e161-3
View the Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness
Issue 1562 · December 17, 2018
Drugs for Chronic Insomnia

Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. Pharmacologic treatment should be used in addition to CBT-I when CBT-I alone is not effective.

Med Lett Drugs Ther. 2018 Dec 17; 60(1562):201-5
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. Pharmacologic treatment should be used in addition to CBT-I when CBT-I alone is not effective.
Issue 1562 · December 17, 2018
Expanded Table: Some Oral Hypnotics for Insomnia (online only)

View the Expanded Table: Some Oral Hypnotics for Insomnia

Med Lett Drugs Ther. 2018 Dec 17; 60(1562):e209-13
View the Expanded Table: Some Oral Hypnotics for Insomnia
Issue 1472 · July 6, 2015
Drugs for Insomnia

Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications, and "natural" remedies. Behavioral approaches such as cognitive behavioral therapy, which are not discussed…

Med Lett Drugs Ther. 2015 Jul 6; 57(1472):95-8
Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications, and "natural" remedies. Behavioral approaches such as cognitive behavioral therapy, which are not discussed here, are also used. Pharmacologic treatment and behavioral therapy are often combined.
Issue 1466 · April 13, 2015
Advice for Travelers

Patients planning to travel to other countries often ask for information about prevention of diarrhea, malaria, and other travel-related conditions. Vaccines recommended for travelers based on their…

Med Lett Drugs Ther. 2015 Apr 13; 57(1466):52-8
Patients planning to travel to other countries often ask for information about prevention of diarrhea, malaria, and other travel-related conditions. Vaccines recommended for travelers based on their destination, length of stay, and planned activities were reviewed in a previous issue.
Issue 1463 · March 2, 2015
Suvorexant (Belsomra) for Insomnia

The FDA has approved suvorexant ( Belsomra – Merck), the first orexin receptor antagonist to become available in the US, for treatment of sleep-onset and/or sleep-maintenance insomnia.

Med Lett Drugs Ther. 2015 Mar 2; 57(1463):29-31
The FDA has approved suvorexant ( Belsomra – Merck), the first orexin receptor antagonist to become available in the US, for treatment of sleep-onset and/or sleep-maintenance insomnia.
Issue 1444 · June 9, 2014 Free
In Brief: Lowering the Dose of Lunesta

The FDA has required the manufacturer of eszopiclone ( Lunesta – Sunovion), a benzodiazepine receptor agonist approved for the treatment of insomnia, to lower the current recommended starting dose to 1 mg…

Med Lett Drugs Ther. 2014 Jun 9; 56(1444):48
The FDA has required the manufacturer of eszopiclone ( Lunesta – Sunovion), a benzodiazepine receptor agonist approved for the treatment of insomnia, to lower the current recommended starting dose to 1 mg for both men and women because a new study found that an evening dose of 3 mg can impair driving skills, memory, and coordination for more than 11 hours. 1 Eszopiclone’s half-life is longer than that of any other drug in its class, which includes zolpidem ( Ambien , and generics) and zaleplon ( Sonata , and generics). All benzodiazepine receptor agonists may impair performance the next morning, including driving. 2 Anterograde amnesia and complex sleep-related behaviors without conscious awareness may also occur. Hallucinations have been reported. Like the benzodiazepines, benzodiazepine receptor agonists are schedule IV controlled substances; withdrawal, dependence, and abuse can occur. 1. FDA Drug Safety Communication. FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose. Available at www.fda.gov. Accessed May 29, 2014. 2. Drugs for insomnia. Treat Guidel Med Lett 2012; 10:57. Download complete U.S. English article